These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7714779)

  • 1. Dynorphin A modulates acute and chronic opioid effects.
    Hooke LP; He L; Lee NM
    J Pharmacol Exp Ther; 1995 Apr; 273(1):292-7. PubMed ID: 7714779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression by dynorphin A-(1-13) of the expression of opiate withdrawal and tolerance in mice.
    Takemori AE; Loh HH; Lee NM
    Eur J Pharmacol; 1992 Oct; 221(2-3):223-6. PubMed ID: 1358653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Des-Tyr1]dynorphin A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay.
    Hooke LP; He L; Lee NM
    J Pharmacol Exp Ther; 1995 May; 273(2):802-7. PubMed ID: 7752083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression by dynorphin A and [des-Tyr1]dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice.
    Takemori AE; Loh HH; Lee NM
    J Pharmacol Exp Ther; 1993 Jul; 266(1):121-4. PubMed ID: 8101214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynorphin A (2-17) attenuates the unconditioned but not the conditioned effects of opiate withdrawal in the rat.
    Shippenberg TS; Funada M; Schutz CG
    Psychopharmacology (Berl); 2000 Sep; 151(4):351-8. PubMed ID: 11026742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-opioid nociceptive activity of human dynorphin mutants that cause neurodegenerative disorder spinocerebellar ataxia type 23.
    Watanabe H; Mizoguchi H; Verbeek DS; Kuzmin A; Nyberg F; Krishtal O; Sakurada S; Bakalkin G
    Peptides; 2012 Jun; 35(2):306-10. PubMed ID: 22531488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both dynorphin A(1-17) and [Des-Tyr1]dynorphin A(2-17) inhibit adenylyl cyclase activity in rat caudate putamen.
    Claye LH; Unterwald EM; Ho A; Kreek MJ
    J Pharmacol Exp Ther; 1996 Apr; 277(1):359-65. PubMed ID: 8613942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynorphin-(1-13): antinociceptive action and its effects on morphine analgesia and acute tolerance.
    Kishioka S; Morita N; Kitabata Y; Yamanishi T; Miyamoto Y; Ozaki M; Yamamoto H
    Jpn J Pharmacol; 1992 Nov; 60(3):197-207. PubMed ID: 1362787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynorphins other than dynorphin A(1-17) lack spinal antianalgesic activity but do act on dynorphin A(1-17) receptors.
    Rady JJ; Fujimoto JM; Tseng LF
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1073-80. PubMed ID: 1684812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynorphin A (1-13), microinjected into the preoptic area, stimulates water intake in rats.
    Shimizu H; Shimomura Y; Negishi M; Kobayashi I; Kobayashi S
    Life Sci; 1989; 45(1):25-30. PubMed ID: 2568571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonopioid motor effects of dynorphin A and related peptides: structure dependence and role of the N-methyl-D-aspartate receptor.
    Shukla VK; Prasad JA; Lemaire S
    J Pharmacol Exp Ther; 1997 Nov; 283(2):604-10. PubMed ID: 9353375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxone and norbinaltorphimine administered intracerebroventricularly antagonize spinal morphine-induced antinociception in mice through the antianalgesic action of spinal dynorphin A (1-17).
    Holmes BB; Fujimoto JM
    J Pharmacol Exp Ther; 1992 Apr; 261(1):146-53. PubMed ID: 1348537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-administration of dynorphin-[1-13] and D-ala2-dynorphin-[1-11] (kappa opioid agonists) in morphine (mu opioid agonist)-dependent rats.
    Khazan N; Young GA; Calligaro D
    Life Sci; 1983; 33 Suppl 1():559-62. PubMed ID: 6319910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynorphin A(1-17) mediates midazolam antagonism of morphine antinociception in mice.
    Rady JJ; Fujimoto JM
    Pharmacol Biochem Behav; 1993 Oct; 46(2):331-9. PubMed ID: 7903457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal tolerance and unidirectional non-cross-tolerance in narcotic pellet-implanted mice.
    Lange DG; Roerig SC; Fujimoto JM; Busse LW
    J Pharmacol Exp Ther; 1983 Jan; 224(1):13-20. PubMed ID: 6681541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substance P N-terminal fragment SP(1-7) attenuates chronic morphine tolerance and affects dynorphin B and nociceptin in rats.
    Zhou Q; Carlsson A; Hallberg M; Nyberg F
    Peptides; 2011 Aug; 32(8):1661-5. PubMed ID: 21763376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action.
    Faden AI; Jacobs TP
    Br J Pharmacol; 1984 Feb; 81(2):271-6. PubMed ID: 6142741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic single dose morphine pretreatment desensitizes mice to the spinal antianalgesic action of dynorphin A (1-17).
    Fujimoto JM; Holmes B
    J Pharmacol Exp Ther; 1990 Jul; 254(1):1-7. PubMed ID: 1973192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: effect of different routes of administration.
    Brugos B; Arya V; Hochhaus G
    AAPS J; 2004 Dec; 6(4):e36. PubMed ID: 15760101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice.
    de Cordé A; Krząścik P; Wolińska R; Kleczkowska P; Filip M; Bujalska-Zadrożny M
    Behav Pharmacol; 2018 Aug; 29(5):393-399. PubMed ID: 29462108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.